NASDAQ: MEDSDatameds Ai Inc Stock
$2.96-0.44 (-12.94%)
Updated Oct 9, 2026
MEDS Price
$2.96
Fair Value Price
N/A
Market Cap
$4.73M
52 Week Low
$0.82
52 Week High
$73.00
P/E
-0.06x
P/B
-0.24x
P/S
1x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.02M
Earnings
-$88.28M
Gross Margin
-90.6%
Operating Margin
-1,026.33%
Profit Margin
-1,100.3%
Debt to Equity
-2.68
Operating Cash Flow
-$14M
Beta
0.91
Next Earnings
Nov 18, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MEDS Overview
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MEDS's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
D
MEDS
Ranked#2 of 2
Ranked#2 of 2
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | B | |
| $1.29 | – | |
| $0.11 | – |
Be the first to know about important MEDS news, forecast changes, insider trades & much more!
MEDS News
Overview
Due Diligence Score
–
Industry Average (18)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MEDS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MEDS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MEDS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MEDS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MEDS due diligence checks available for Premium users.
Valuation
MEDS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
-6.61x
Market
49.9x
MEDS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.24x
Industry
28.37x
MEDS's financial health
Profit margin
Revenue
$1.8M
Net Income
-$18.4M
Profit Margin
-1,031.7%
MEDS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MEDS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$32.8M
Liabilities
$52.3M
Debt to equity
-2.68
MEDS's short-term liabilities ($39.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MEDS's long-term liabilities ($12.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MEDS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MEDS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$242.1k
Financing
$5.5M
MEDS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MEDS vs Pharmaceutical Retailer Stocks
Datameds Ai Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.